Hydrophobic binary mixtures containing amphotericin B as lipophilic solutions for the treatment of cutaneous leishmaniasis

被引:0
|
作者
Augis, Luc [1 ]
Nguyen, Canh Hung [1 ,2 ]
Ciseran, Cecile [1 ]
Wacha, Andras [3 ]
Nome, Francoise Mercier [4 ,5 ]
Domenichini, Severine [4 ]
Sizun, Christina [6 ]
Fourmentin, Sophie [7 ]
Legrand, Francois-Xavier [1 ]
机构
[1] Univ Paris Saclay, Inst Galien Paris Saclay, CNRS, F-91400 Orsay, France
[2] Hanoi Univ Pharm, Dept Pharmaceut, 13-15 Thanh Tong, Hanoi, Vietnam
[3] Inst Mat & Environm Chem, Res Ctr Nat Sci, Magyar Tudosok Korutja 2, H-1117 Budapest, Hungary
[4] Univ Paris Saclay, Ingn & Plateformes Serv Innovat Therapeut, Inserm, CNRS, F-91400 Orsay, France
[5] Univ Paris Saclay, Inserm, Inflammat Microbiome & Immunosurveillance, F-91400 Orsay, France
[6] Univ Paris Saclay, Inst Chim Subst Nat, CNRS, UPR 2301, F-91198 Gif Sur Yvette, France
[7] Univ Littoral Cote dOpale, Unite Chim Environm & Interact Vivant, UR 4492, UCEIV, F-59140 Dunkerque, France
关键词
Cutaneous leishmaniasis; Amphotericin B; Deep eutectic solvents; Low transition temperature mixtures; Lipophilic solution; MTT assay; Franz diffusion cells; DEEP EUTECTIC SOLVENTS; IONIC LIQUIDS; CHOLINE CHLORIDE; INTERMOLECULAR INTERACTIONS; CARBOXYLIC-ACIDS; MICROEXTRACTION; EXTRACTION; PHASE; GREEN; PHOSPHONIUM;
D O I
10.1016/j.ijpharm.2024.124486
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cutaneous leishmaniasis, caused by Leishmania parasites, requires treatments with fewer side effects than those currently available. The development of a topical solution based on amphotericin B (AmB) was pursued. The considerable interest in deep eutectic solvents (DESs) and their remarkable advantages inspired the search for a suitable hydrophobic excipient. Various mixtures based on commonly used hydrogen bond donors (HBDs) and acceptors (HBAs) for DES preparations were explored. Initial physical and in-vitro screenings showed the potential of quaternary phosphonium salt-based mixtures. Through thermal analysis, it was determined that most of these mixtures did not exhibit eutectic behavior. X-ray scattering studies revealed a sponge-like nanoscale structure. The most promising formulation, based on a combination of trihexyl(tetradecyl)phosphonium chloride and 1-oleoyl-rac-glycerol, showed no deleterious effects through histological evaluation. AmB was fully solubilized at concentrations between 0.5 and 0.8 mg & sdot;mL- 1, depending on the formulation. The monomeric state of AmB was observed by circular dichroism. In-vitro irritation tests demonstrated acceptable viability for AmBbased formulations up to 0.5 mg & sdot;mL- 1. Additionally, an ex-vivo penetration study on pig ear skin revealed no transcutaneous passage, confirming AmB retention in healthy, unaffected skin.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Nanoemulsions containing amphotericin b and paromomycin for the treatment of cutaneous leishmaniasis
    Cunha, Nicolas Fontenele Callipo
    de Siqueira, Luciana Betzler de Oliveira
    Garcia, Andreza Raposo
    Rodrigues, Igor Almeida
    Matos, Ana Paula dos Santos
    Ricci Junior, Eduardo
    Monteiro, Mariana Sato de Souza Bustamante
    ACTA TROPICA, 2024, 254
  • [2] Treatment of cutaneous leishmaniasis with liposomal amphotericin B
    del Rosal Rabes, T.
    Baquero-Artigao, F.
    Gomez Fernandez, C.
    Garcia Miguel, M. J.
    de Lucas Laguna, R.
    ANALES DE PEDIATRIA, 2010, 73 (02): : 101 - 102
  • [3] Lipsosomal Amphotericin B for Treatment of Cutaneous Leishmaniasis
    Wortmann, Glenn
    Zapor, Michael
    Ressner, Roseanne
    Fraser, Susan
    Hartzell, Josh
    Pierson, Joseph
    Weintrob, Amy
    Magill, Alan
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 1028 - 1033
  • [4] Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
    Ubals, Maria
    Bosch-Nicolau, Pau
    Sanchez-Montalva, Adrian
    Salvador, Fernando
    Aparicio-Espanol, Gloria
    Sulleiro, Elena
    Silgado, Aroa
    Soriano-Arandes, Antoni
    Espiau, Maria
    Ferrer, Berta
    Pou, Diana
    Trevino, Begona
    Molina, Israel
    Garcia-Patos, Vicente
    PATHOGENS, 2021, 10 (10):
  • [5] Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
    Goyonlo, Vahid Mashayekhi
    Vosoughi, Elham
    Kiafar, Bita
    Nahidi, Yalda
    Momenzadeh, Akram
    Taheri, Ahmad Reza
    INDIAN JOURNAL OF DERMATOLOGY, 2014, 59 (06) : 631
  • [6] Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B
    Erat, Tugba
    An, Isa
    DERMATOLOGIC THERAPY, 2022, 35 (09)
  • [7] Topical Amphotericin B for the treatment of localized cutaneous leishmaniasis
    Alcantara-Reifs, Carmen Maria
    Garnacho-Saucedo, Gloria
    Salido-Vallejo, Rafael
    Velez Garcia-Nieto, Antonio
    DERMATOLOGIC THERAPY, 2017, 30 (01)
  • [8] Amphotericin B is usually underdosed in the treatment of experimental cutaneous leishmaniasis
    Sifontes-Rodriguez, Sergio
    Chaviano-Montes de Oca, Claudia Sissely
    Monzote-Fidalgo, Lianet
    Meneses-Gomez, Susana
    Mollineda-Diogo, Niurka
    Escario Garcia-Trevijano, Jose Antonio
    ARS PHARMACEUTICA, 2022, 63 (03) : 253 - 262
  • [9] Topical amphotericin B for cutaneous leishmaniasis
    Vardy, D
    Barenholz, Y
    Cohen, R
    Zvulunov, A
    Biton, A
    Klaus, S
    Frankenburg, S
    ARCHIVES OF DERMATOLOGY, 1999, 135 (07) : 856 - 857
  • [10] Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis
    Wortmann, GW
    Fraser, SL
    Aronson, NE
    Davis, C
    Miller, RS
    Jackson, JD
    Oster, CN
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 1006 - 1007